

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Rodney G. Wilson, et al.

Serial No.: 10/674,582

Filed: September 29, 2003

For: METHODS OF DISPENSING
GENERIC PHARMACEUTICAL
PRODUCTS

Examiner: Not Yet Assigned

Art Unit:

INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicant requests that these documents be considered by the Examiner before issuance of the next action and made of record in this file. The Examiner is also asked to initial and return a copy of the enclosed PTO/SB/08A Form to evidence such consideration.


This Information Disclosure Statement is being filed in accordance with the following provisions:

- ☒ CFR §1.97(b)(1). Within three months of the filing date of the application. No fee is required.
- ☒ 37 CFR § 1.97(b)(3). To the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits. No fee is required.


If it is determined that a fee is required as set forth in 37 CFR § 1.17(p) or 1.17(i)(1), or if any additional fees are required, please charge such fee to Deposit Account No. 02-4467. A duplicate copy of this document is enclosed.

Respectfully submitted,

By:



James B. Surber
Registration No. 48,381
BRYAN CAVE LLP
211 North Broadway, Suite 3600
St. Louis, Missouri 63102-2750
(314) 259-2390 (Telephone)
(314) 259-2020 (Facsimile)



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/674,582
Filing Date	September 29, 2003
First Named Inventor	Rodney G. Wilson
Group Art Unit	
Examiner Name	Not yet assigned

Sheet	2	of	2	Attorney Docket Number	C018497/0106453
-------	---	----	---	------------------------	-----------------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	C1	"FREE Orange Card" pamphlet enrollment form of GLAXOSMITHKLINE	
✓	C2	Internet enrollment form of TOGETHER RX, LLC	
✓	C3	"Real Savings. Real Easy." Pamphlet enrollment form of TOGETHER RX, LLC	
✓	C4	Patient Assistance Program enrollment form of TAP PHARMACEUTICALS, INC.	
✓	C5	Patient Assistance Program enrollment form of SOLVAY PHARMACEUTICALS	
✓	C6	Patient Assistance Program enrollment form of SHIRE US INC.	
✓	C7	Patient Assistance Program enrollment form of SCHERING	
✓	C8	Patient Assistance Program form of PURDUE	
✓	C9	Patient Assistance Program form of ORPHAN MEDICAL	
✓	C10	Patient Assistance Program form of NOVARTIS	
✓	C11	Patient Assistance Program form of PROCTER & GAMBLE	
✓	C12	Patient Assistance Program form of CONNECTION TO CARE	
✓	C13	Patient Assistance Program form of MGI PHARMA	
✓	C14	Patient Assistance Program form of LIGAND PHARMACEUTICALS	
✓	C15	Patient Assistance Program form of FAULDING LABORATORIES	
✓	C16	Patient Assistance Program form of FIRST HORIZON PHARMACEUTICAL CORPORATION	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.